Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine in External Dacrocystorhinostomy
NCT06808295Phase 1Recruiting
- Sponsor
- Research Institute of Ophthalmology
- Start
- Apr 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of dexmedetomidine in nasolacrimal duct obstruction (NLDO) (2 arms), sponsored by Research Institute of Ophthalmology. Primary endpoint: Maintained hemodynamic values while reducing the anesthetic requirements. Started Apr 2024; status: recruiting.
02
Drugs
dexmedetomidine
03
Conditions
nasolacrimal duct obstruction (NLDO)
Beyond the preview
Go deeper on NCT06808295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06808295.